Ron Wyden

DemocratORSenatorServing since 2023
Sponsored
70
Cosponsored
358
Amendments
112
Votes cast
217
Committees
14

Sponsored bills

View all
S. 5081In committee

Congressional Trade Powers Reform Act of 2026

S. 5040In committee

A bill to amend the Internal Revenue Code of 1986 to impose limitations on high-income taxpayers with large retirement account balances.

S.J.Res. 198In committee

A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".

S. 4997In committee

Nitrous Oxide Inhalation Prevention Act

S. 5006In committee

Work Without Worry Act of 2026

S. 5002In committee

Duster Inhalation Prevention Act

S. 4773In committee

DASH Act

S. 4740In committee

A bill to amend the Foreign Intelligence Surveillance Act of 1978 to improve transparency, and for other purposes.

Vote record

  • On the Resolution
    S.Res. 817
    Jul 30, 2026 · Resolution Agreed to
    nay
  • Unspecified
    S.J.Res. 181
    Jul 30, 2026 · Unspecified
    yea
  • On the Motion to Proceed
    S.J.Res. 199
    Jul 30, 2026 · Motion to Proceed Rejected
    yea
  • On the Cloture Motion
    S.Res. 817
    Jul 29, 2026 · Cloture Motion Agreed to
    nay
  • On the Motion to Proceed
    H.R. 5334
    Jul 29, 2026 · Motion to Proceed Agreed to
    nay
  • On Cloture on the Motion to Proceed
    H.R. 5334
    Jul 28, 2026 · Cloture on the Motion to Proceed Agreed to
    nay
  • On the Nomination
    Jul 28, 2026 · Nomination Confirmed
    nay
  • On the Cloture Motion
    Jul 27, 2026 · Cloture Motion Agreed to
    nay
  • On the Nomination
    Jul 23, 2026 · Nomination Confirmed
    nay
  • On the Nomination
    Jul 23, 2026 · Nomination Confirmed
    nay

Amendments

  • To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer.

Latest activity

18 events unlock with a free account
18 rulemakings this week
Create free account →